



FOR IMMEDIATE RELEASE
November 17th, 2022

Washington, D.C. – The Special Operations Association of America is proud to stand with 17 other SOF-founded-and-directed Veteran organizations to support Senator Booker (NJ-D) and Senator Paul (KY-R) in their newly announced “Breakthrough Therapies Act.”

The “*Breakthrough Therapies Act*” would provide an alternative registration process for Schedule I research, thereby reducing the regulatory barriers surrounding the research of Schedule I psychedelic compounds and streamlining access to psychedelic-assisted therapy. Senator Booker eloquently summarized the issue:

“Recent studies suggest that some Schedule I substances such as MDMA and psilocybin could represent an enormous advancement for the treatment of severe post-traumatic stress disorder, depression, and addiction. Unfortunately, regulatory red tape and a series of bureaucratic hurdles involved in studying Schedule I substances impede critical research on these and other promising Schedule I compounds. This bill reduces these unreasonably burdensome rules and regulations that delay or prevent researchers from studying – and patients from accessing – this entire class of potential medicines.”

In so doing, the “Breakthrough Therapies Act” will remove the current barriers between Special Operations Forces Veterans and the groundbreaking, life-saving treatments they need. In Dr. Paul’s own words:

“I’m proud to co-lead this legislation with Sen. Booker that would streamline the registration process for breakthrough therapies currently restricted by outdated drug classifications. This bill will make it easier for researchers to conduct studies that can lead to breakthrough therapies to treat patients battling serious and life-threatening conditions.”

We call upon all Senators, and soon Congress, to unanimously support and pass this bill into law—honoring the dedication and sacrifices of our Veteran community.

Media Contact:
Ryan Deal
Ryan@SOAA.org